Replies to post #535501 on NorthWest Biotherapeutics Inc (NWBO)

[norisknorewards]

Mike, why not 40b bo price, I can see natural price progression not getting there, but bo, sure why not

[ATLnsider]

FeMike, I think the disconnect here is that you are making a NWBO share price prediction within 3 to 6 months, after DCVax-L approval in the U.K. only.

However, most NWBO longs here are basing their valuation projections more long-term, after regulatory approvals in the US, Canada, UK, Germany and the rest of the EU. The U.K. only does not have an addressable GBM market of 12,000 patients per year, but the U.K., plus Germany, plus the rest of the EU, does have an addressable GBM market (nGBM + rGBM) of at least 12,000 patients per year.

I don’t believe most NWBO longs here are planning to sell all or most of their NWBO shares in the next 3 to 6 months.

[Doc logic]

FeMike,

By Q2 the 3 year forward looking PE will be factored in along with buyout value of the platform based on development potential which newer legislation will impact by moving approved products forward faster. This will happen because institutions will be taking positions soon and providing coverage all while retail starts to really wake up and understand what is going on.
Once approval takes hold as a given after SNO coverage and commercialization readiness announcements by NWBO are published this will be accomplished. There won’t be a huge amount of time before institutions will gain access to establishing their positions as moves by NWBO to get up listed after announcements is also a given. One big buyer taking a position could launch this and NWBO hired 2 merger and acquisition/ uplisting folks to help ready them for this process.
I have no need to prove myself correct and respect your position. I’ll leave it at that; ). Best wishes.